Neurotoxin

Revance Provides an Update on DAXXIFY® Commercial Launch and Preliminary Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Monday, January 9, 2023
Biotechnology, FDA, Pharmaceutical, Health, Speech, Spasticity, Education, Therapy, GAAP, Death, Neuromuscular Disorders, Faculty, Patient, Growth, Food, Hubli railway division, Traction, Investment, Neurotoxin, Dysphagia, Pharmaceutical industry, Video game

Revance Therapeutics, Inc. (RVNC) today provided an update on its early experience program for DAXXIFY® and its preliminary unaudited fourth quarter and full year 2022 financial results.

Key Points: 
  • Revance Therapeutics, Inc. (RVNC) today provided an update on its early experience program for DAXXIFY® and its preliminary unaudited fourth quarter and full year 2022 financial results.
  • Revance expects preliminary unaudited DAXXIFY® revenue from PrevU, its early experience program, to be between $10.5 million and $11.5 million in the fourth quarter 2022, the first quarter of limited commercial availability.
  • Revance expects preliminary unaudited fourth quarter 2022 service revenue from OPUL® and the legacy HintMD fintech platform to be between $2.5 million and $3.5 million and full year 2022 preliminary unaudited service revenue of between $6.5 million and $7.5 million.
  • The company expects to provide its 2023 GAAP and Non-GAAP operating expense guidance in its fourth quarter 2022 earnings announcement.

Revance Announces U.S. FDA Acceptance of Supplemental Biologics License Application (sBLA) for DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia

Retrieved on: 
Friday, January 6, 2023
Biotechnology, FDA, Pharmaceutical, Health, Prescription Drug User Fee Act, PDUFA, Food, Muscle, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, ASPEN, Injection, Torticollis, Patient, Neuromuscular Disorders, Speech, Physician, Safety, Neurotoxin, FDA, Dysphagia, Spasticity, Hubli railway division, Pharmaceutical industry, MD

Results from the ASPEN-OLS study reinforced the safety findings reported from ASPEN-1 study, as well as the efficacy of DAXXIFY® with up to four repeat treatments.

Key Points: 
  • Results from the ASPEN-OLS study reinforced the safety findings reported from ASPEN-1 study, as well as the efficacy of DAXXIFY® with up to four repeat treatments.
  • “Painful symptom re-emergence is very common for patients with cervical dystonia and up until now physicians have not been able to fully address this issue with existing treatment options,” said Peter McAllister, MD.
  • The effects of DAXXIFY® and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.
  • The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

AEON Biopharma to Become Publicly Listed via Merger with Priveterra Acquisition Corp.; Accelerating Clinical Development of ABP-450 (prabotulinumtoxinA) Injection to Treat Debilitating Medical Conditions in Neurology

Retrieved on: 
Tuesday, December 13, 2022
AEON, Exhibit, Acquisition, BLA, Physician, Sub, Allergan, Neurology, Wardwell, Person, Security (finance), FDA, Reading, Sale, Economics, Prospectus, Latham & Watkins, Neurotoxin, Proxy, Atomic mass, Sumathi Best Television Current Reporting Award, Toxin (comics), History, Sustainability Accounting Standards Board, SPAC, Patient, Therapy, Form, Management, Pharmaceutical industry

Upon closing of the proposed transaction, the combined company will operate as AEON Biopharma, Inc. and is expected to list on Nasdaq under the ticker symbol "AEON".

Key Points: 
  • Upon closing of the proposed transaction, the combined company will operate as AEON Biopharma, Inc. and is expected to list on Nasdaq under the ticker symbol "AEON".
  • AEON has assembled a seasoned team with expertise in neuroscience research, development, regulatory affairs, operations, manufacturing, and commercialization.
  • Marc Forth, CEO and President of AEON Biopharma, said: “We’re making great progress across our late-stage clinical programs as we continue the development of ABP-450 for the treatment of multiple debilitating medical conditions.
  • AEON is a clinical stage biopharmaceutical company focused on developing ABP-450 (prabotulinumtoxinA) injection for the treatment of debilitating medical conditions with an initial focus on the neurology and gastroenterology markets.

Medical Aesthetics Market to Surpass $34,124 Million Revenue by 2030, Says P&S Intelligence

Retrieved on: 
Tuesday, December 13, 2022
Development, Scar, Skin, Patient, Neurotoxin, Government, Ageing, Renewable energy, Cosmetics, Transport, Growth

NEW YORK, Dec. 13, 2022 /PRNewswire/ --According to the latest market research study published by P&S Intelligence, in 2021, the medical aesthetics market had a total size of $11,892.0 million, and it is predicted to hit $34,124.0 million by 2030, progressing at a rate of 12.4% from 2021 to 2030.

Key Points: 
  • NEW YORK, Dec. 13, 2022 /PRNewswire/ --According to the latest market research study published by P&S Intelligence, in 2021, the medical aesthetics market had a total size of $11,892.0 million, and it is predicted to hit $34,124.0 million by 2030, progressing at a rate of 12.4% from 2021 to 2030.
  • This is mainly because of the development of technologically advanced and easy-to-use products and the mounting need for aesthetic treatments among people.
  • These are some of the significant changes that typically happen with the aging of an individual.
  • The APAC market is projected to grow at a significant rate in the years to come.

Athira Pharma Presents Preclinical Data Supporting Therapeutic Potential of HGF/MET Platform at Neuroscience 2022 Conference

Retrieved on: 
Wednesday, November 16, 2022
COVID-19, HGF, Dementia, Athira Pharma, Neurotoxin, Communication, Nature, MET, Doctor of Philosophy, Pain, Neuroprotection, Alpha-synuclein, Brain, Neurotoxicity, Patient, Society, Nerve, Hepatocyte growth factor, Neurodegeneration, Research, Diabetic neuropathy, Security (finance), Peripheral neuropathy, STZ, Rotenone, PD, Lewy body, Oxidative stress, Neuron, Investment, Safety, RATS, Pharmaceutical industry, Aroma compound, Birth control, Neuroscience, L. Athira Krishna

BOTHELL, Wash., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced data highlighting the potential therapeutic benefits of enhancing the HGF/MET neurotrophic system in preclinical models of Parkinson’s disease (PD) and diabetic neuropathy. These findings were presented at the Neuroscience 2022 conference, hosted by the Society for Neuroscience.

Key Points: 
  • These findings were presented at the Neuroscience 2022 conference, hosted by the Society for Neuroscience.
  • The data presented at Neuroscience 2022 show that fosgonimeton (ATH-1017) promotes neuroprotection, reduces alpha-synuclein aggregation in vitro, and improves motor performance in animal models of Parkinsons disease.
  • An oral nanosymposium presentation highlighted the neuroprotective effects of fosgonimeton against neuronal damage and motor deficits in preclinical models of Parkinsons disease.
  • These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements.

Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights

Retrieved on: 
Monday, November 14, 2022
FDA, Fast Track, Neurotoxin, Journal, Communication, Marketing, Clinical trial, R, PIN, NCT, MAD, Pathology, Accounting, Cash balance plan, G&A, SAD, Pharmacokinetics, Neurodegeneration, Safety, Research, Security (finance), Division, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Administration, Research and development, Therapy, ABOS, Neuron, COVID-19, Phase 1, Mab, Food, General counsel, Patient, Pharmaceutical industry, Communications satellite, Internet service provider, Airline, Vaccine, Acumen

ET

Key Points: 
  • ET
    CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targeted therapeutics for Alzheimers disease (AD), today reported financial results for the third quarter of 2022 and provided a business update.
  • During the third quarter, we remained focused on executing INTERCEPT-AD, our Phase 1 clinical trial of ACU193 in patients with early AD.
  • Acumen anticipates completing enrollment in the first quarter of 2023 and reporting topline data from this trial in the second half of 2023.
  • Additional information will be made available in other filings that Acumen makes from time to time with the SEC.

UAE Medical Aesthetic Devices (Energy-Based Aesthetic Device v/s Non-Energy-Based Aesthetic Device) Markets, Competition, Forecast & Opportunities, 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, November 14, 2022
Surgery, Hardware, Other Health, Health, Technology, Elective surgery, Neurotoxin, Hair removal, Type, Surgeon, Injection, Social media, Aesthetics, Female, Cellulite, Application, IPL, Patient, Health, Risk management, Dentistry, Medical device

The "UAE Medical Aesthetic Devices Market, By Type of Device (Energy-Based Aesthetic Device v/s Non-Energy-Based Aesthetic Device), By Application, By End User, By Region, Competition Forecast & Opportunities, 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "UAE Medical Aesthetic Devices Market, By Type of Device (Energy-Based Aesthetic Device v/s Non-Energy-Based Aesthetic Device), By Application, By End User, By Region, Competition Forecast & Opportunities, 2027" report has been added to ResearchAndMarkets.com's offering.
  • Multiple applications that are involved in medical aesthetic treatments increase the demand for medical aesthetic devices, which will fuel market expansion for medical aesthetic devices in the UAE during the next five years.
  • To estimate and forecast the market size of UAE medical aesthetic devices market from 2023 to 2027 and growth rate until 2027.
  • To classify and forecast the UAE medical aesthetic devices market based on type of device, application, end user, region, and company.

Dermatologist Dr. Ellen Turner Receives Allergan Medical Institute® (AMI) Designation

Retrieved on: 
Tuesday, November 8, 2022
Dermatology, Gel, Knowledge, Neurotoxin, Injection, Family, Facial muscles, Medicine, AMI, Allergan, Skin, Patient, MD, Dentistry, Medical device

DALLAS, Nov. 08, 2022 (GLOBE NEWSWIRE) --

Key Points: 
  • Double board-certified dermatologist and Allergan Medical Institute Facial Aesthetics Injector Trainer Dr. Ellen Turner, who provides a full spectrum of dermatology in the Dallas area , has completed extensive training in injectables and has achieved outstanding credentials in the field.
  • As of this year, after years of extensive training, Dr. Turner earned an Allergan Medical Institute (AMI) designation, demonstrating her remarkable level of skill and knowledge as a practitioner.
  • Allergan Medical Institute aims to enhance patient results and provide advanced, science-backed, expert-approved medical education to healthcare professionals worldwide.
  • Dr. Ellen Turner makes a point of offering the most modern, in-demand technology and advanced techniques available in dermatology.

Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease

Retrieved on: 
Tuesday, November 1, 2022
Security (finance), Goal, MAD, NCT, CSF, Neurodegeneration, U.S. Securities and Exchange Commission, Solubility, SEC, Biomarker, Research, GLOBE, Blood, Cerebrospinal fluid, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pathology, Neurotoxin, Safety, Neuron, AD, NASDAQ, Private Securities Litigation Reform Act, SAD, ABOS, Pharmacokinetics, Food, Patient, Fast Track, Therapy, Phase 1, Mab, Pharmaceutical industry, Vaccine, Acumen

The article was published in the Journalof Prevention of Alzheimers Disease and outlines the design of its ongoing Phase 1 INTERCEPT-AD trial for ACU193 and planned criteria for advancing to a Phase 2/3 clinical trial based on recent advancements in clinical research on Alzheimers disease.

Key Points: 
  • The article was published in the Journalof Prevention of Alzheimers Disease and outlines the design of its ongoing Phase 1 INTERCEPT-AD trial for ACU193 and planned criteria for advancing to a Phase 2/3 clinical trial based on recent advancements in clinical research on Alzheimers disease.
  • Pending discussions with regulators, if the interim analysis is positive, and the trial is expanded, the Phase 2/3 trial could potentially serve as a registration trial.
  • The Phase 1 trial design and clinical development plan for ACU193 reflect several advances in Alzheimers disease research methodology and incorporate moving from a first-in-humans trial directly to a registration-quality Phase 2/3 trial which uses an adaptive design.
  • The publication, titled ACU193, a Monoclonal Antibody that Selectively Binds Soluble A Oligomers: Development Rationale, Phase 1 Trial Design, and Clinical Development Plan, can be viewed online here .

Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease

Retrieved on: 
Monday, October 24, 2022
U.S. Securities and Exchange Commission, Therapy, SEC, Review, Amyloid-related imaging abnormalities, Neurotoxin, MAD, Private Securities Litigation Reform Act, ABOS, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NASDAQ, Patient, Research, Security (finance), Synapse, Collection, Food, Goal, Trial of the century, Neuron, Cell death, Mab, Pharmacokinetics, Safety, SAD, AD, Fast Track, GLOBE, FDA, NCT, Pathology, Neurodegeneration, ARIA, Pharmaceutical industry, Vaccine, Acumen

We are encouraged to receive Fast Track designation for ACU193, reflecting its potential clinical utility to treat Alzheimers disease, said Daniel OConnell, President and Chief Executive Officer of Acumen.

Key Points: 
  • We are encouraged to receive Fast Track designation for ACU193, reflecting its potential clinical utility to treat Alzheimers disease, said Daniel OConnell, President and Chief Executive Officer of Acumen.
  • We look forward to collaborating with the FDA to advance the development of ACU193.
  • The Fast Track designation allows Acumen to have more frequent engagement with the FDA to discuss development plans and clinical study design for ACU193 to ensure collection of appropriate data to support evaluation for approval.
  • Acumens scientific founders pioneered research on AOs, which a growing body of evidence indicates are primary triggers of Alzheimers disease pathology.